Literature DB >> 16024154

Subchronic oral toxicity study with cyadox in Wistar rats.

Guijie Fang1, Qinghua He, Shiqi Zhou, Daju Wang, Yanling Zhang, Zonghui Yuan.   

Abstract

To investigate the potential subchronic toxicity of cyadox, groups of 15 male and 15 female Wistar rats were fed with diets containing cyadox (0, 50, 150 or 2500 mg/kg) or olaquindox (150 mg/kg), approximately equivalent to cyadox 5, 15, 250 or olaquindox 15 mg/kg b.w./day, for 13 weeks. Five rats/sex/group were sacrificed on days 30, 60 and 90. No test-material-related changes were seen in mortality, clinical signs, hematology, clinical chemistry, organ weight data and macroscopic examinations. Except that body weights of both sexes of the 2500 mg/kg cyadox group were significantly lower than controls beginning after the second week of treatment. Body weights of females of 150 mg/kg olaquindox group were significantly lower than those of the control group at weeks 3 and 4. Other groups were unaffected by treatments. Histopathological observations revealed that 2500 mg/kg cyadox or 150 mg/kg olaquindox induced swelling and fatty degeneration of the hepatocytes and proximal renal tubular epithelial cells. It was for the first time that changes were found in the liver and kidneys of rats fed 2500 mg/kg cyadox. The no-observed-adverse-effect level (NOAEL) of cyadox for rats was estimated to be 150 mg/kg dietary dose level.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024154     DOI: 10.1016/j.fct.2005.06.003

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  7 in total

1.  Pharmacokinetics and Metabolism of Cyadox and Its Main Metabolites in Beagle Dogs Following Oral, Intramuscular, and Intravenous Administration.

Authors:  Adeel Sattar; Shuyu Xie; Lingli Huang; Zahid Iqbal; Wei Qu; Muhammad A Shabbir; Yuanhu Pan; Hafiz I Hussain; Dongmei Chen; Yanfei Tao; Zhenli Liu; Mujahid Iqbal; Zonghui Yuan
Journal:  Front Pharmacol       Date:  2016-08-03       Impact factor: 5.810

2.  Olaquindox disrupts tight junction integrity and cytoskeleton architecture in mouse Sertoli cells.

Authors:  Di Wu; Chun-Jie Huang; Xiao-Fei Jiao; Zhi-Ming Ding; Jia-Yu Zhang; Fan Chen; Yong-Sheng Wang; Xiang Li; Li-Jun Huo
Journal:  Oncotarget       Date:  2017-08-16

3.  Preparation, characterization and pharmacokinetics of cyadox nanosuspension.

Authors:  Adeel Sattar; Dongmei Chen; Lishun Jiang; Yuanhu Pan; Yanfei Tao; Lingli Huang; Zhenli Liu; Shuyu Xie; Zonghui Yuan
Journal:  Sci Rep       Date:  2017-05-23       Impact factor: 4.379

4.  Development of quinoxaline 1, 4-dioxides resistance in Escherichia coli and molecular change under resistance selection.

Authors:  Wentao Guo; Haihong Hao; Menghong Dai; Yulian Wang; Lingli Huang; Dapeng Peng; Xu Wang; Hailan Wang; Min Yao; Yawei Sun; Zhenli Liu; Zonghui Yuan
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

5.  Mechanism of porcine liver xanthine oxidoreductase mediated N-oxide reduction of cyadox as revealed by docking and mutagenesis studies.

Authors:  Chigang Chen; Guyue Cheng; Haihong Hao; Menghong Dai; Xu Wang; Lingli Huang; Zhenli Liu; Zonghui Yuan
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

Review 6.  Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions.

Authors:  Guyue Cheng; Wei Sa; Chen Cao; Liangliang Guo; Haihong Hao; Zhenli Liu; Xu Wang; Zonghui Yuan
Journal:  Front Pharmacol       Date:  2016-03-21       Impact factor: 5.810

7.  Mequindox Induced Genotoxicity and Carcinogenicity in Mice.

Authors:  Qianying Liu; Zhixin Lei; Qin Wu; Deyu Huang; Shuyu Xie; Xu Wang; Yuanhu Pan; Zonghui Yuan
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.